Adoptive cell therapy (ACT) using tumor-reactive T lymphocytes is a promising approach for treating advanced cancer. Successful tumor eradication depends primarily on the expansion and survival of the adoptively transferred T cells. Lymphodepletion using total body irradiation (TBI) and administering high dose IL2 have been used with ACT to promote T cell expansion and survival to achieve maximal therapeutic effects. However, TBI and high dose IL2 increase the risk for major complications that impact overall survival. Here we describe an alternative approach to TBI and high dose IL2 for optimizing ACT, resulting in dramatic therapeutic effects against established melanomas in mice.
Introduction
CD8 T lymphocytes recognize and destroy tumor cells through perforin/granzyme Bmediated lysis or via the production of cytostatic lymphokines (1) (2) (3) (4) . Tumor-reactive CD8
T cells recognize peptide antigens that associate with major histocompatibility complex (MHC) class I molecules on the surface of tumor cells (5) . In the case of malignant melanoma, peptides can be derived from melanosomal differentiation antigens such as gp100, and tyrosinase-related proteins (6) (7) (8) . One factor limiting the effectiveness of T cells to recognize tumors is related to the T cell receptor (TCR) antigen affinity, which requires being sufficiently high to enable T cell activation when tumor cells express low density of peptide/MHC-I complexes (9, 10) . Since in many instances normal tissues also express the tumor-associated proteins, immunological tolerance precludes the induction of T cells expressing high affinity TCRs, limiting the effectiveness of many therapeutic vaccines (11, 12) . In view of this, adoptive immunotherapy utilizing high avidity CD8 T cells has been explored to treat established and aggressive malignant diseases such as melanoma (13, 14) . In addition to TCR affinity, other factors may determine the effectiveness of adoptive cell therapy (ACT), such as the ability of the T cells to expand and survive in vivo after adoptive transfer into the tumor-bearing hosts. Lymphokines such as IL2, IL7 and IL15 are critical for expansion and survival of T cells and generating longlasting memory CD8 T cells (15) (16) (17) . Some procedures have been used to increase the access of the transferred T cells to these lymphokines such as the co-administration of high dose IL2 (18, 19) and lymphodepletion using total body irradiation (TBI) or 4 chemotherapy (14, (20) (21) (22) (23) . Unfortunately these procedures generate severe toxic effects that can be life threatening.
The B16 mouse melanoma model has been widely used and proven to be valuable for developing effective ACT strategies for melanoma patients (24) . In this model the use of high avidity CD8 T cells obtained from Pmel-1 TCR transgenic mice was effective against large-established tumors but required lymphodepletion, high dose IL2 and active immunization using a recombinant vaccinia virus vaccine after the T cell transfers (25) .
Our goal was to determine whether effective ACT against established B16 melanoma could be attained in the absence of the concomitant harmful procedures (high dose IL2, live vaccines and lymphodepletion). We assessed the ability of TriVax (26) , a potent, non- 
Methods

Mice and cell lines
C57BL/6 (B6) mice were from Charles River (Wilmington, MA). Congenic B6 (CD45.1) and Pmel-1 mice (CD90.1) were from The Jackson Laboratory (Bar Harbor, ME). Animal care 6 ng/mL GM-CSF and 5 ng/mL IL4 and matured with 20 ng/ml TNFα (PeproTech). For PD1 blockade, anti-PD-L1 mAb was administered i.p. (200 µg/dose) on days 2, 4, 6, 8 and 10 after TriVax. IL2/anti-IL2 mAb complexes (IL2Cx), were prepared by incubating 2 µg recombinant mouse IL2 with 10 µg anti-mouse IL2 (JES6-5H4) per dose for 18 h at 4 °C.
IL2Cx were administered i.p. on days 2, 3, 5 and 7 after TriVax. For adoptive transfer using endogenous, vaccine-generated T cells, B6 mice received 3 X 10 6 Trp1 455 -specific CD8 T cells generated in B6 mice immunized with Trp1 455/9M TriVax. CD8 T cells were purified from spleens (Miltenyi Biotec, Auburn, CA) 10 days after the second immunization, followed by culture with irradiated (60 Gy) B16 cells for 7 days in the presence of 50 IU/ml IL2 and 5 ng/ml IL7 (PeproTech, Rocky Hill, NJ). The cells used in ACT were >50% tetramer-positive for Trp1 455 .
Evaluation of cellular immune responses
For measuring antigen-specific CD8 T cell responses, peripheral blood samples or splenocytes were stained with FITC-anti-MHC class II, PerCP Cy5.5-anti-CD8a, and PEconjugated tetramers (or in some instances APC-anti-CD90.1, for Pmel-1 cells). For intracellular staining, splenocytes were incubated with 5 μg/ml peptide for 6 h at 37 °C and stained for intracellular cytokines, IL2, IFNγ and TNFα. Fluorescence was measured using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Ashland, OR). To evaluate the in vitro T cell tumor recognition, 1 X 10 5 purified antigen-specific CD8 T cells (adjusted by tetramer staining) from TriVax immunized mice were co-cultured with various numbers of irradiated (60 Gy) B16 cells in 96-well plates for 2 days. Antigen-induced IFNγ was measured in culture supernatants by 7 ELISA (eBioscience).
Anti-tumor effects
B6 mice were injected s.c. with 3 or 5 X 10 5 B16 cells and 7 (or 12 days) later, they received Pmel-1 splenocytes or activated Trp1 455 reactive T cells. The following day the mice were vaccinated and subsequently received IL2Cx or PD1 blockade as described above. Tumor growth was monitored every 3-4 days in individual tagged mice by measuring 2 opposing diameters with a set of calipers. Results are presented as the mean tumor size (area in mm 2 ) ± SD for every treatment group at various time points until the termination of the experiment (usually when tumors in the control group reached 2 cm diameter).
Peptide/MHC-I elution and quantification
A mild acid peptide elution procedure (27) using viable cells was used to compare the amounts of mgp100 25 and Trp1 455 found on B16 cells. Briefly, 1 X 10 9 B16 cells were incubated at 1 X 10 8 cells/ml for 5 min in a mild acid buffer (131 mM Citric Acid, 66 mM Na 2 HPO 4 , pH 3.0). The supernatant was filtered through a 0.45 µm membrane and concentrated with SepPAKC 18 cartridges (Waters, Milford, MA). Peptides were separated on an HPLC system (Agilent Technologies, Santa Clara, CA) equipped with a C 18 column (Vydac Grace, Columbia, MD). The peptides were collected into 81 fractions that were optimized by the retention times of mgp100 25 and Trp1 455 synthetic peptides. For estimation the amounts of mgp100 25 and Trp1 455 peptides, four adjacent HPLC fractions, predicted to contain these peptides based on HPLC runs using synthetic peptides, were resuspended in culture medium and were pulsed for onto 1 X 10 5 RMA-S/CD80 cells. After 1 h, 3 X 10 5 CD8 8 T cells (Pmel-1 or Trp1 455 specific) were added to the peptide-pulsed RMA-S/CD80 cells and the cultures were incubated for 40 h at 37 °C. Standard curves were performed using serial dilutions of synthetic peptides mgp100 25 and Trp1 455 pulsed onto the RMA-S/CD80 cells. Culture supernatants were assayed for IFNγ production using ELISA kits. The amounts of peptides contained in the HPLC fractions derived from the B16 cell acid eluate were estimated by measuring the amount of IFNγ produced and comparing these measurements to the values obtained in the linear portion of the synthetic peptide standard curves, taking into account dilution factors and adding the values obtained for all fractions for each peptide that stimulated the T cells.
MHC binding and stabilization assays
Peptide/MHC binding and dissociation assays were performed following similar procedures as described by van Stipdonk (28) . TAP-deficient RMA-S cells were incubated with serial dilutions of various peptides for 18 h. For peptide-dependent stabilization assays, RMA-S cells were loaded with 20 μg/ml peptides for 1 h, washed, and incubated in AIM-V medium at 37 °C for various time points. After these incubations, surface expression of H-2Db was measured by flow cytometry using FITC-conjugated monoclonal antibody (28-14-8, eBioscience).
Statistical analyses
The results are representative of data obtained from at least two independent experiments. Statistical significance to assess numbers of antigen specific CD8 T cells was determined by unpaired Student's t tests. Tumor sizes between 2 populations throughout time were analyzed for significance using 2-way analysis of variance (ANOVA). All 9 analyses and graphics were done using Prism 5.01 software (GraphPad, San Diego, CA). Pvalues less than 0.01 were considered to be statistically significant.
Results
Effects of vaccination in anti-tumor efficacy of ACT
Three peptide vaccination modes were compared for their ability to enhance the efficacy of ACT with Pmel-1 T cells against 7-day s.c. B16 tumors. Pmel-1 T cells recognize the mgp100 25 (EGSRNQDWL), H-2Db-restricted epitope expressed by B16 and normal melanocytes (25) . The hgp100 25 peptide (KVPRNDQWL) function as a heteroclitic T cell epitope because it binds with higher affinity to H-2Db (29) . Peptide hgp100 25 administered in IFA, did not decrease the tumor growth rate as compared to the unvaccinated mice (Fig. 1A) . DCs pulsed with hgp100 25 had a modest therapeutic effect while TriVax (hgp100 25 peptide mixed with poly-IC and anti-CD40 antibody and administered i.v.) (26) had a substantially higher anti-tumor effect. TriVax immunization without Pmel-1 ACT had a negligible therapeutic effect.
Next we assessed the roles that each of the components of TriVax play in the generation of the antitumor effect with Pmel-1 ACT. The vaccine containing all three components (TriVax), was significantly superior to the administration of peptide alone, peptide plus poly-IC or peptide plus anti-CD40 antibody (Fig. 1B) . Substitution of the hgp100 25 peptide for an irrelevant peptide (Ova 55 ) in TriVax slightly delayed tumor growth (compared to the no treatment control) but was clearly not as effective as hgp100 25 not enhance the expansion of the Pmel-1 cells when adoptively transferred into the tumorbearing hosts (Fig. 1C) . Measurements of the Pmel-1 cell numbers in blood at various time points showed that TriVax was the most effective vaccine in expanding the Pmel-1 cells (Fig. 1C) . However, these numbers decreased substantially by days 25-35 (50-75%, respectively), which correlated with the observed resumed tumor growth (Fig. 1B) .
Similar experiments performed in tumor-free mice also indicated that TriVax was substantially more effective than peptide alone, peptide plus Poly-IC or peptide plus ant-CD40 antibody in expanding Pmel-1 cells ( Supplementary Fig. S1A-B) . Moreover, the large decrease in Pmel-1 cell numbers observed in TriVax immunized tumor-bearing mice where the cells disappeared by day 45 (Fig. 1C) was not apparent in tumor-free mice, where more than 50% of the cells remained at a similar time point (Supplementary Fig.   S1C ).
Effects of IL2, PD1 blockade and T cell dose in anti-tumor efficacy of ACT
We have reported that TriVax induces massive T cell responses that are substantially higher than those generated by other modes of vaccination (26, 30) . We hypothesized that the number of T cells that expand after vaccination determine the anti-tumor effects of ACT. To further increase T cell numbers we evaluated the use of IL2 in the form of IL2Cx, which have been shown to potentiate in vivo CD8 T cell expansion (31, 32) . In addition, since it has been reported that B16 cells express PD-L1, a ligand for the inhibitory receptor PD1 found on activated T cells, we evaluated the use PD1 blockade using anti-PD-L1 antibodies (33) (34) (35) . The results shown in Figure 2A effects observed in ACT with the TriVax IL2Cx (or PD1 blockade) combination were accompanied by a substantial improvement in the sustained numbers of expanded Pmel-1 cells (Fig. 2B) . Interestingly, the administration of TriVax with IL2Cx or PD1 blockade in the absence of ACT had a small but significant therapeutic effect that did not correlate with the presence of endogenously generated T cells by the hgp100 25 peptide (Figs. 2A-B, open symbols).
Next, we compared three doses of Pmel-1 cells and the use of TriVax with IL2Cx or PD1 blockade for their therapeutic effects against 7-day established B16 tumors. Indeed, the number of Pmel-1 cells used for ACT correlated with the anti-tumor efficacy (Fig. 2C) .
However, regardless of the Pmel-1 cell dose, TriVax alone was not able to achieve complete tumor rejections. Nevertheless, the implementation of IL2Cx or PD1 blockade together with TriVax resulted in numerous tumor rejections.
The tumor size may impact the effectiveness of T cell immunotherapy. ACT using Pmel-1 cells followed by TriVax was used to treat 12-day established B16 tumors (~1 cm diameter). Under these circumstances, ACT followed by TriVax alone reduced the median tumor growth rate only by ~5 days (Fig. 3A) . The addition of PD1 blockade to the therapy reduced significantly the median tumor growth rate( ~22 days), but no tumor rejections were observed. In contrast, IL2Cx with TriVax resulted in tumor rejection in 80% of the mice. When the frequency of Pmel-1 cells in blood was measured it became evident that the combination using IL2Cx helped to maintain higher numbers of the adoptively transferred T cells as compared to TriVax alone or TriVax/PD1 blockade (Fig. 3B) . (Fig. 4A) . With the addition of PD1 blockade or IL2Cx to TriVax, the T cell expansion increased to 100-fold and 370-fold, respectively.
Functional assessment of the expanded Pmel-1 cells revealed that production of IFNγ, IL2 and TNFα induced by antigen stimulation was similar in mice receiving TriVax alone or combined with PD1 blockade or IL2Cx (Fig. 4B) . The expression of PD1 on the T cells could have an impact on their effectiveness against PD-L1 expressing tumor cells. Figure   4C shows that the levels of PD1 were lower on the Pmel-1 cells obtained from (Fig. 4D) . Thus, the addition of IL2Cx or PD1 blockade in ACT/TriVax improved both quantitatively and qualitatively the Pmel-1 CAN-11-3246 response. Notably, costimulatory antibodies to OX40 and 4-1BB, which are known to enhance the magnitude and quality of T cell responses to vaccination, were not as effective as anti-PD-L1 in increasing T cell numbers or in potentiating the therapeutic effect of ACT/TriVax (Supplementary Fig. S2 ).
Efficacy of ACT using TriVax generated polyclonal CD8 T cells
The source of CD8 T cells for ACT in humans can vary, such as utilizing in vitro expanded tumor-infiltrating lymphocytes (TILs), or genetically modified CD8 T cells transduced with genes encoding TCR chains for a specific tumor epitope. Another source of antigen-specific T cells are those generated through vaccination and subsequently expanded in tissue culture prior to ACT. We explored this approach by generating antigen-specific CD8 T cells through TriVax immunization using the heteroclitic Trp1 455/9M peptide. ACT using vaccinederived CD8 T cells specific for the Trp1 455 was effective in reducing the rate of tumor growth and the concomitant use of PD1 blockade or IL-2Cx further increased the therapeutic effect (Fig. 5A) 
T cells in blood, 6 days after vaccination and that by day 18 (corresponding to day 25-post tumor injection), these numbers decrease to ~2% (H. Cho and E. Celis, unpublished). Thus, the high responses observed in Figure 5B most likely resulted from the transferred CD8 T cells. Supporting the assumption that most of the Trp1 455 -specific T cells observed after ACT and TriVax are derived from the transferred cells is the data shown in Figure 5D (the same experiment presented in Figure 5C ), where it is demonstrated that all of the antigen specific cells were derived from the donor (CD45.2) mice.
As mentioned previously, it has been reported that decreasing the numbers of lymphocytes in the host, for example via TBI prior to ACT can enhance the anti-tumor therapeutic effect (20, 23) . However, we observed that TBI-induced lymphodepletion, administered 1 day prior to ACT with Trp1 455-463/9M specific CD8 T cells did not further augment therapeutic effects (Supplementary Fig. S3A ) or antigen-specific CD8 T cell levels ( Supplementary Fig. S3B ) in the TriVax treated mice regardless of whether they received or not IL2Cx.
T cell epitope levels on tumor cells determine the effectiveness of ACT
The results presented above indicate that ACT using Pmel-1 CD8 T cells, specific for the mgp100 25 was more effective than ACT utilizing Trp1 455 -specific T cells. One possibility that might explain these differences would be if the antigen avidity of the TCR transgenic Pmel-1 cells was higher than the vaccine generated Trp1 455 T cells. However, peptide titration curve comparisons between these T cells revealed that the Trp1 455 -specific T cells exhibited a substantially higher avidity (~30-fold), as compared to Pmel-1 cells (Supplementary Fig. S4A ). Another possible explanation for the superior therapeutic effect of Pmel-1 cells could be if the B16 cells expressed higher levels of mgp100 25 /H-2Db than Trp1 455 / H-2Db. To study this possibility, MHC-I binding peptides on B16 cells were eluted with mild acid treatment and the amounts of the two T cell epitopes were measured as described in "Methods". The results indicated that ~100-fold more of mgp100 25 was obtained from the B16 acid eluates as compared to Trp1 455 (Supplementary Fig. S4B ).
The peptide/MHC-I density on the B16 cells for a specific epitope will be determined by numerous factors such as peptide binding affinity for its MHC-I (36) and by the amount of peptide epitope produced by the MHC-I antigen-processing pathway. Using MHC-I stabilization assays, we compared the capacity of mgp100 25 and Trp1 455 to bind to empty H-2Db molecules expressed by RMA-S cells. Notably, Trp1 455 was ~100 times more effective in binding to H-2Db as compared to mgp100 25 and the positive control LCMV 33 ( Supplementary Fig. S4C ). The peptide dissociation off rate from MHC-I will also affect the cell surface density of peptide/MHC-I complexes (37). Both mgp100 25 and Trp1 455 had similar dissociation rates (Supplementary Fig. S4D ). These results suggest that the higher amounts of mgp100 25 /H-2Db levels on B16, as compared to the levels of One possible mechanism for enhancing anti-tumor recognition could be an improvement in T cell avidity by increasing expression levels of costimulatory/adhesion T cell receptors such as CD8/lck, CD2 and lmphocyte function-associated antigen-1 (LFA-1). An important observation was that the addition of IL2Cx and to some extent PD1 blockade prevented the observed loss of the Pmel-1 cells expanded by TriVax in tumor-bearing hosts, which could be explained by the reduced levels of PD1 induced by these adjuncts. 
Notwithstanding, the overall results indicate that the therapeutic anti-tumor potentiation induced by IL2Cx and PD1 blockade in this model of ACT followed by TriVax is derived by an enhancement of both the quantitative and qualitative aspects of the CD8 T cell response.
We also presented evidence that polyclonal, vaccine-generated CD8 T cells were effective in ACT/TriVax. However, in contrast with Pmel-1 ACT, no complete tumor rejections were obtained with the Trp1 455/9M TriVax-generated T cells with IL2Cx or PD1 blockade. The higher anti-tumor efficacy of the Pmel-1 T cells compared to the Trp1 455/9M -generated CD8 T cells may be explained the observations that B16 contained ~100-times more mgp100 25 /H-2Db than Trp1 455 /H-2Db complexes. We attempted to induce endogenous, vaccine-generated CD8 T cells using hgp100 25 TriVax for ACT. However, the antigen avidity of the endogenous hgp100 25 TriVax generated T cells was 10-fold lower as compared to the Pmel-1 cells and these cells failed to recognize tumor cells (Supplementary Fig. S5 ). It is likely that the Pmel-1 cells express a TCR in the high end of antigen affinity spectrum because of the procedure used to select the T cells from which the TCR genes were clones (6) . Nonetheless, the therapeutic anti-tumor effects obtained in ACT using the vaccine-generated Trp1 455/9M T cells were not meager, especially when combined with IL2Cx or PD1 blockade and offer an alternative to those instances where high affinity TCR genes are not available for transduction into effector T cells. 
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